Home › Major Depressive Disorder › California › San Diego
Pag-aaral pangklinika para sa Major Depressive Disorder sa San Diego, CA
16 pag-aaral para sa Major Depressive Disorder ang naghahanap ng mga kalahok sa mga site sa loob at paligid ng San Diego (sa loob ng humigit-kumulang 30 milya). Buksan ang pag-aaral upang makita kung sino ang makakasali at kung paano makipag-ugnayan sa koponan ng pag-aaral.
Opisyal na teksto ng pag-aaral (English)
ACP-211 Monotherapy for Major Depressive Disorder With Inadequate Antidepressant Response
Nagre-recruitPhase 2
- Kadima Neuropsychiatry Institute, La Jolla · 11 mi ang layo
A Phase 3 Trial of DT120 for Major Depressive Disorder (Ascend)
Nagre-recruitPhase 3
- Kadima Neuropsychiatry Institute, San Diego
A Study to Evaluate TNX-102 SL Monotherapy Versus Placebo in Participants With Major Depressive Disorder (MDD)
Nagre-recruitPhase 2
- Artemis Institute For Clinical Research - San Diego, San Diego
A Study to Evaluate the Effectiveness of Valbenazine in Adult Participants With Tardive Dyskinesia (TD) Who Remain Symptomatic While Receiving or After Stopping a Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor
Nagre-recruitPhase 4
- Neurocrine Clinical Site, San Diego
Spaced Transcranial Direct Current Stimulation for Treatment-Resistant Depression: A Home-Based Feasibility and Safety Study
Nagre-recruit
- UCSD Interventional Psychiatry, San Diego
A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder (X-NOVA3)
Nagre-recruitPhase 3
- Artemis Institute for Clinical Research, San Diego
- Center for Neurohealth, La Jolla · 11 mi ang layo
A Study to Evaluate the Effectiveness of DT-101 in Patients With Depression
Nagre-recruitPhase 2
- Draig Clinical Site, San Diego
Enhancing Veteran-Clinical Collaboration in VA PRRCs
Nagre-recruit
- VA San Diego Healthcare System, San Diego, CA, San Diego
Clinical Assessment of Response in the Treatment of Depression With Daytime Sleepiness Using Solriamfetol
Nagre-recruitPhase 3
- Clinical Research Site, San Diego
Long-Term Study to Assess the Safety and Tolerability of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
Nagre-recruitPhase 3
- Neurocrine Clinical Site, San Diego
A Study to Assess the Efficacy, Safety and Tolerability of VLS-01 Buccal Film, Compared to Placebo in Patients With Treatment Resistant Depression (ELUMINA)
Nagre-recruitPhase 2
- Kadima Neuropsychiatry Institute, La Jolla · 11 mi ang layo
Mindfulness Engaged Neurostimulation for Depression (MEND II)
Nagre-recruitPhase 2
- UC San Diego Health Psychiatry, San Diego
Maintenance rTMS for Depression (Maitr-De)
Nagre-recruit
- University of California, San Diego, San Diego
ATLAS-1: Advanced Trial for Longitudinal Assessment in Salma 1
Nagre-recruitObservasyonal na pag-aaral
- Salma Health, La Jolla · 11 mi ang layo
Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
Nagre-recruitPhase 3
- Neurocrine Clinical Site, San Diego
A Study to Evaluate the Efficacy of AXS-05 Compared to Bupropion in Preventing the Relapse of Depressive Symptoms
Nagre-recruitPhase 4
- Clinical Research Site, San Diego
Pag-aaral para sa Major Depressive Disorder sa ibang lungsod
- New York City, NY36 pag-aaral
- Boston, MA31 pag-aaral
- Atlanta, GA25 pag-aaral
- Philadelphia, PA23 pag-aaral
- Orlando, FL19 pag-aaral
- Miami, FL18 pag-aaral
- Chicago, IL17 pag-aaral
- Tampa, FL17 pag-aaral
- Houston, TX16 pag-aaral
- Little Rock, AR14 pag-aaral
- Austin, TX13 pag-aaral
- Las Vegas, NV13 pag-aaral
Iba pang pag-aaral sa San Diego
- Non-Small Cell Lung Cancer48 pag-aaral
- Kanser sa Suso41 pag-aaral
- Kanser (lahat ng uri)32 pag-aaral
- Kanser sa Prostate31 pag-aaral
- Metastatic Cancer30 pag-aaral
- Colorectal Cancer25 pag-aaral
- Kanser sa Ovary24 pag-aaral
- Kanser sa Pancreas24 pag-aaral
- Kanser sa Baga23 pag-aaral
- Obesity23 pag-aaral
- Pagkabigo ng Puso23 pag-aaral
- Depression21 pag-aaral
Mula sa ClinicalTrials.gov, na-kuha noong Okt 6, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.